Shares of RIBOLIFE-B (06938) climbed as much as 5% during the trading session, with the stock last up 3.73% at HK$62.60, reflecting a turnover of approximately HK$11.08 million. The company recently disclosed its interim results for fiscal year 2026, reporting revenue of RMB 420 million, a 304% year-on-year increase. Net profit for the period stood at RMB 23 million, marking a turnaround from a loss in the prior year, while cash and cash equivalents at period-end reached RMB 2.24 billion.

The improvement in financial performance is primarily attributed to the recognition of licensing revenue from global collaboration projects and the continued advancement of cooperative milestones. Meanwhile, the company has maintained its research and development investments in core clinical pipelines and its innovative delivery platform.